Hepatitis C Virus Infection among Hematopoietic Cell Transplant Donors and Recipients: American Society for Blood and Marrow Transplantation Task Force Recommendations

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 11, 2015, Pages 1870-1882

  Torres, Harrys A ^a   Chong, Pearlie P ^b   De Lima, Marcos ^c   Friedman, Mark S ^d   Giralt, Sergio ^e   Hammond, Sarah P ^f   Kiel, Patrick J ^g   Masur, Henry ^h   McDonald, George B ⁱ   Wingard, John R ^j   Gambarin Gelwan, Maya ^e  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h NATIONAL INSTITUTES OF HEALTH   (United States)

ⁱ USA   (United States)

^j UNIVERSITY OF FLORIDA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CHRONIC HEPATITIS C; DONOR; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MEDICAL SOCIETY; NONHUMAN; PATIENT MONITORING; REVIEW; UNITED STATES; ADVERSE EFFECTS; BLOOD; BONE MARROW TRANSPLANTATION; DISEASE MANAGEMENT; DRUG EFFECTS; EVIDENCE BASED MEDICINE; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; IMMUNOLOGY; ISOLATION AND PURIFICATION; LIVER; PATHOLOGY; PRACTICE GUIDELINE; VIROLOGY;

ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; VIRUS ANTIBODY;

ALANINE TRANSAMINASE; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; BONE MARROW TRANSPLANTATION; DISEASE MANAGEMENT; EVIDENCE-BASED MEDICINE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER; PRACTICE GUIDELINES AS TOPIC; SOCIETIES, MEDICAL; TISSUE DONORS; TRANSPLANT RECIPIENTS; UNITED STATES;

EID: 84943405486     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2015.07.033     Document Type: Review

References (70)

1. AASLD/IDSA/IAS-USA. Recommendations for testing, managing, and treating hepatitis C. Available at: Accessed July 27, 2015. http://hcvguidelines.org/.
2. Torres H.A., Mahale P., Blechacz B., et al. Effect of hepatitis C virus infection in patients with cancer: addressing a neglected population. J Natl Comprehen Cancer Netw 2015, 13:41-50.
3. Peffault de Latour R., Asselah T., Levy V., et al. Treatment of chronic hepatitis C virus in allogeneic bone marrow transplant recipients. Bone Marrow Transplant 2005, 36:709-713.
4. Tomblyn M., Chiller T., Einsele H., et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009, 15:1143-1238.
5. Strasser S.I., Myerson D., Spurgeon C.L., et al. Hepatitis C virus infection and bone marrow transplantation: a cohort study with 10-year follow-up. Hepatology 1999, 29:1893-1899.
6. Ramos C.A., Saliba R.M., de Padua L., et al. Impact of hepatitis C virus seropositivity on survival after allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Haematologica 2009, 94:249-257.
7. Nakasone H., Kurosawa S., Yakushijin K., et al. Impact of hepatitis C virus infection on clinical outcome in recipients after allogeneic hematopoietic cell transplantation. Am J Hematol 2013, 88:477-484.
8. Evans A.T., Loeb K.R., Shulman H.M., et al. Fibrosing cholestatic hepatitis C after hematopoietic cell transplantation: report of 3 fatal cases. Am J Surg Pathol 2015, 39:212-220.
9. Ljungman P., Johansson N., Aschan J., et al. Long-term effects of hepatitis C virus infection in allogeneic bone marrow transplant recipients. Blood 1995, 86:1614-1618.
10. Tomas J.F., Pinilla I., Garcia-Buey M.L., et al. Long-term liver dysfunction after allogeneic bone marrow transplantation: Clinical features and course in 61 patients. Bone Marrow Transplant 2000, 26:649-655.
11. Strasser S.I., Sullivan K.M., Myerson D., et al. Cirrhosis of the liver in long-term marrow transplant survivors. Blood 1999, 93:3259-3266.
12. Peffault de Latour R., Levy V., Asselah T., et al. Long-term outcome of hepatitis C infection after bone marrow transplantation. Blood 2004, 103:1618-1624.
13. Shimizu T., Kasahara M., Tanaka K. Living-donor liver transplantation for chronic hepatic graft-versus-host disease. N Engl J Med 2006, 354:1536-1537.
14. Andreoni K.A., Lin J.I., Groben P.A. Liver transplantation 27 years after bone marrow transplantation from the same living donor. N Engl J Med 2004, 350:2624-2625.
15. Smith B.D., Morgan R.L., Beckett G.A., et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. Morbid Mortal Wkly Rep 2012, 61:1-32.
16. Moyer V.A. US Preventive Services Task Force. Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2013, 159:349-357.
17. Shuhart M.C., Myerson D., Childs B.H., et al. Marrow transplantation from hepatitis C virus seropositive donors: transmission rate and clinical course. Blood 1994, 84:3229-3235.
18. Foundation for the Accreditation of Cellular Therapies, International Standards for Cellular Therapy, Product Collection, Processing, and Administration, 5th ed, 2012. University of Nebraska Medical Center, Nebraska Medical Center, Omaha, NE.
19. Food and Drug Administration, Guidance for Industry: Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products, dated 2007. http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Tissue/ucm091345.pdf.
20. Ghany M.G., Strader D.B., Thomas D.L., Seeff L.B. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009, 49:1335-1374. American Association for the Study of Liver D.
21. Locasciulli A., Testa M., Valsecchi M.G., et al. The role of hepatitis C and B virus infections as risk factors for severe liver complications following allogeneic BMT: a prospective study by the Infectious Disease Working Party of the European Blood and Marrow Transplantation Group. Transplantation 1999, 68:1486-1491.
22. Kyvernitakis A, Mahale P, Popat UR, et al. Hepatitis C virus infection in patients undergoing hematopoietic cell transplantation in the era of direct-acting antiviral agents. The 2015 Annual Meeting of the American Society of Clinical Oncology (ASCO), May 29-June 2, 2015. Chicago, IL J Clin Oncol 33, 2015 (suppl; abstr 7090).
23. Hsiao H.H., Liu Y.C., Wang H.C., et al. Hepatitis C transmission from viremic donors in hematopoietic stem cell transplant. Transplant Infect Dis 2014, 16:1003-1006.
24. Beckerich F., Hezode C., Robin C., et al. New nucleotide polymerase inhibitors to rapidly permit hematopoietic stem cell donation from a positive HCV-RNA donor. Blood 2014, 124:2613-2614.
25. Sagnelli E., Pisaturo M., Stanzione M., et al. Clinical presentation, outcome, and response to therapy among patients with acute exacerbation of chronic hepatitis C. Clin Gastroenterol Hepatol 2013, 11:1174-1180.
26. Mahale P., Kontoyiannis D.P., Chemaly R.F., et al. Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients. J Hepatol 2012, 57:1177-1185.
27. McGovern B.H., Birch C.E., Bowen M.J., et al. Improving the diagnosis of acute hepatitis C virus infection with expanded viral load criteria. Clin Infect Dis 2009, 49:1051-1060.
28. Torres H.A., Davila M. Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. Nat Rev Clin Oncol 2012, 9:156-166.
29. Vento S., Cainelli F., Mirandola F., et al. Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus. Lancet 1996, 347:92-93.
30. Varma A., Saliba R.M., Torres H.A., et al. Outcomes and survival in hepatitis C virus seropositive lymphoma and myeloma patients after autologous stem cell transplantation. Am J Gastroenterol 2014, 109(Suppl 2). The 79th Annual Meeting of the American College of Gastroenterology, abstr 2075.
31. Chahal P., Levy C., Litzow M.R., Lindor K.D. Utility of liver biopsy in bone marrow transplant patients. J Gastroenterol Hepatol 2008, 23:222-225.
32. Wallace M.J., Narvios A., Lichtiger B., et al. Transjugular liver biopsy in patients with hematologic malignancy and severe thrombocytopenia. J Vasc Intervent Radiol 2003, 14:323-327.
33. Rockey D.C., Caldwell S.H., Goodman Z.D., et al. Liver biopsy. Hepatology 2009, 49:1017-1044.
34. Chou R., Wasson N. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review. Ann Intern Med 2013, 158:807-820.
35. AASLD and Vibration Controlled Transient Elastography. Available at: Accessed March 19, 2015. http://theliverlab.com/downloads/AASLD_Endorses_FibroScan.pdf.
36. Afdhal N.H., Bacon B.R., Patel K., et al. Accuracy of FibroScan, compared with histology, in analysis of liver fibrosis in patients with hepatitis B or C: a United States multicenter study. Clin Gastroenterol Hepatol 2015, 13:772-779.
37. Hamidieh A.A., Shazad B., Ostovaneh M.R., et al. Noninvasive measurement of liver fibrosis using transient elastography in pediatric patients with major thalassemia who are candidates for hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2014, 20:1912-1917.
38. Auberger J., Graziadei I., Clausen J., et al. Non-invasive transient elastography for the prediction of liver toxicity following hematopoietic SCT. Bone Marrow Transplant 2013, 48:159-160.
39. Vance E.A., Soiffer R.J., McDonald G.B., et al. Prevention of transmission of hepatitis C virus in bone marrow transplantation by treating the donor with alpha-interferon. Transplantation 1996, 62:1358-1360.
40. Surapaneni S.N., Hari P., Knox J., et al. Suppressive anti-HCV therapy for prevention of donor to recipient transmission in stem cell transplantation. Am J Gastroenterol 2007, 102:449-451.
41. Hogan W.J., Maris M., Storer B., et al. Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients. Blood 2004, 103:78-84.
42. Arcaini L., Vallisa D., Rattotti S., et al. Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi. Ann Oncol 2014, 25:1404-1410.
43. Charlton M., Gane E., Manns M.P., et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology 2015, 148:108-117.
44. Reddy K.R., Everson G.T., Flamm S.L., et al. Ledipasvir/sofosbuvir with ribavirin for the treatment of hcv in patients with post transplant recurrence: preliminary results of a prospective, multicenter study. Hepatology 2014, 60(Suppl). The 65th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2014.
45. Copegus (Ribavirin; package insert). Genentech Inc: South San Francisco, CA, 2011.
46. Afdhal N., Reddy K.R., Nelson D.R., et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014, 370:1483-1493.
47. Afdhal N., Zeuzem S., Kwo P., et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014, 370:1889-1898.
48. Feld J.J., Kowdley K.V., Coakley E., et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014, 370:1594-1603.
49. Ferenci P., Bernstein D., Lalezari J., et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014, 370:1983-1992.
50. Lawitz E., Sulkowski M.S., Ghalib R., et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014, 384:1756-1765.
51. Osinusi A., Kohli A., Marti M.M., et al. Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study. Ann Intern Med 2014, 161:634-638.
52. Product information: Daklinza (Daclatasvir; package insert). Bristol-Myers Squibb Company, Princeton, NJ, 2015.
53. Peyrin-Biroulet L., Cadranel J.F., Nousbaum J.B., et al. Interaction of ribavirin with azathioprine metabolism potentially induces myelosuppression. Aliment Pharmacol Therap 2008, 28:984-993.
54. Victrelis (boceprevir; package insert). Merck Sharp & Dohme Corporation: Whitehouse Station, NJ, 2014.
55. Viekira pak (ombitasvir, paritaprevir, ritonavir, and dasabuvir; package insert). AbbVie Inc.: North Chicago, Il. 2015.
56. Incivek (telaprevir; package insert). Vertex Pharmaceuticals Inc: Cambridge, MA, 2013.
57. Olysio (simeprevir; package insert). Janssen Therapeutics: Titusville, NJ, 2014.
58. Harvoni (ledipasvir and sofosbuvir; package insert). Gilead Sciences, Inc., Foster City, CA, 2014.
59. Mathias A., Cornpropst M., Clemons D., et al. No clinically significant pharmacokinetic drug-drug interactions between sofosbuvir (GS-7977) and the immunosuppressants, cyclosporine A or tacrolimus in healthy volunteers. Hepatology 2012, 56(Suppl 1):1063A-1064A. The 63rd Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2012 [abstract 1869].
60. Ouwerkerk-Mahadevan S., Simion A., Mortier S., et al. No clinically significant interaction between the investigational HCV protease inhibitor TMC435 and the immunosuppressives cyclosporine and tacrolimus. Hepatology 2012, 56(Suppl 1):213A. The 63rd Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2012 [abstract 80].
61. Garg V., van Heeswijk R., Lee J.E., et al. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011, 54:20-27.
62. Hulskotte E., Gupta S., Xuan F., et al. Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. Hepatology 2012, 56:1622-1630.
63. Coilly A., Roche B., Dumortier J., et al. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. J Hepatol 2014, 60:78-86.
64. Tischer S., Fontana R.J. Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting. J Hepatol 2014, 60:872-884.
65. Badri P., Dutta S., Coakley E., et al. Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir. Am J Transplant 2015, 15:1313-1322.
66. Kwo P.Y., Mantry P.S., Coakley E., et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med 2014, 371:2375-2382.
67. Ljungman P., Locasciulli A., de Soria V.G., et al. Long-term follow-up of HCV-infected hematopoietic SCT patients and effects of antiviral therapy. Bone Marrow Transplant 2012, 47:1217-1221.
68. Jacobson I.M., McHutchison J.G., Dusheiko G., et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011, 364:2405-2416.
69. Poordad F., McCone J., Bacon B.R., et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011, 364:1195-1206.
70. Jacobson I.M., Dore G.J., Foster G.R., et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2014, 384:403-413.